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Background and Aims: Despite the widespread distribution of hepatitis B virus 
(HBV) infection and the ongoing controversy about HBV immunization, surprisingly, 
few published studies examined in detail the economic impact of HBV infection. The 
aim of this study is to calculate the medical burden of the government and the 
productivity loss of society for four health states related to hepatitis B (HB), namely 
chronic hepatitis B (CHB), compensated cirrhosis (CC), decompensated cirrhosis (DC) 
and hepatocellular carcinoma (HCC). 
Methodology: The medical histories of a sample of 194 Hepatology patients and 59 
Oncology patients at the Prince of Wales Hospital (PWH) were investigated in this 
retrospective study. For each patient in the sample, the window of investigation starts 
from the first day the patient was tested positive for carrying HB-related diseases 
through a period until December 2001. Within the study window，each patient's 
medical history was studied in detail. 
Results: The empirical results are broadly divided into three parts: Firstly, the average 
monthly direct medical cost (DMC) per patient for the four patient groups was 
respectively HK$485.38, HK$548.11, HK$ 1,446.99 and HK$9,684.19(7.8HK Dollars 
= 1 US Dollar). HCC was the predominant cost driver among HB-related diseases, 
accounting for over 50% of all direct costs. Economic data from government statistics 
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and other sources were used to calculate the cost of disease-related job loss and 
reduced work productivity. Overall, the average losses of annual working days per 
patient of the four patient groups are 2.5, 2.52, 5.81 and 10.02 days respectively. 
Inpatient care represents the largest source of productivity loss. HCC generally causes 
premature death, which represents another source of productivity loss. Male's mean 
onset age is 57.2, female's is 64.6. If the retirement age were set at 65, the mean 
productivity loss per patient as a result of premature death would be $1,039,883.91. 
Conclusions: This study confirms that HBV poses a significant cost burden to the 
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Chapter 1 ： Introduction 
HBV is a mostly double-stranded DNA virus in the Hepadnaviridae family. It 
causes hepatitis in human while the related virus in this family cause hepatitis in 
ducks, ground squirrels and woodchucks. (Poynard. T. 2002) It is a highly contagious 
virus that attacks the liver. In the mildest case, some patients even may not know 
they were infected, and the virus may go away in six months. But some people 
become carriers for life and keep infecting other people. Some go on to have chronic 
liver disease. After becoming a carrier, cirrhosis, or worse still, HCC, may develop. 
According to medical investigation, the chances of getting liver cancer for hepatitis 
B(HB) carriers are up to 300 times higher than for non-carriers. 
The Center for Disease Control and Prevention (CDC) in the US estimate that 
each year about 240,000 Americans became infected with HBV. One out of 20 
people in US has infected with HBV during their lifetime. Although HB is relatively 
rare in the US, it is endemic in parts of Asia where millions of individuals may be 
infected. Blood, blood products and sexual transmission transmit HBV horizontally. 
It is also transmitted vertically from mother to infant during perinatal period，which 
is a major mode of transmission in regions where HB is endemic. 
Hong Kong, with a Chinese population exceeding 95%, is an endemic area 
known for HBV infection. Health Authority records show that currently more than 
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700,000 persons in Hong Kong are HB carriers\ The actual and potential costs of 
CHB treatment and care are therefore substantial. However, there have been few 
studies on direct medical cost (DMC) of CHB and its complications in Hong Kong. 
Based on trend analysis, it is anticipated that the incidence and prevalence of HB will 
continue to rise and will translate into a significant overall economic impact. In view 
of the unique health care financing system in Hong Kong, where the government 
shoulders over 95% of the total medical expenses in public hospitals, the need to 
study the cost impact of long-term diseases with multiple complications such as HB 
is imminent. 
In Europe, despite the widespread distribution of HBV infection and the 
ongoing controversy about its immunization, surprisingly few published studies 
examined in detail the economic impact of HBV infection. In the US, while clinical 
and economic studies on HB-related diseases are plenty, concerns are mostly placed 
on the cost-benefit analysis of vaccination. To find out who should have the priority 
to receive vaccination to maximize the benefits to society, researchers have measured 
the economic burden resulted from the attempts to stop the spread of HB V. In the 
field of HB, however, specialized studies in the US on the estimation ofHB's DMC 
have been few. The most recent ones are Marilyn et al (1999), Yang et al (2001) and 
1 Surveillance of Viral Hepatitis in Hong Kong. Hong Kong Department of Health, 2001 
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Chan et al (2001)2. These three studies have something in common: the calculation 
of medical and social cost of HB-related diseases, i.e. CHB, cirrhosis and HCC. 
Their approaches vary in terms of methodology and assumptions. 
According to the data provided by the Department of Health, on average, every 
one in ten people are infected with HBV. In the later stages of infection, serious 
diseases and complications such as cirrhosis and HCC were estimated to have 
developed in 10% to 20% of CHB carriers (Public Health Report, 2001). This 
illustrates how serious the situation is. With an estimation of the direct and indirect 
cost of the health states related to HB, one would be able to gauge the societal 
impacts of the disease. The aim of this study is to calculate the DMC and indirect 
medical cost (IMC) in the four health states evolved from HB, namely chronic 
hepatitis B (CHB), compensated cirrhosis (CC), decompensated cirrhosis (DC) and 
hepatocellular carcinoma (HCC). On the one hand, the medical expenditures of the 
government on these diseases were examined. On the other hand, the productivity 
loss resulted from these HB-related diseases was estimated. Through this study, it is 
hoped that readers can realize how costly the HB-related diseases are, thereby raising 
their awareness, and ultimately encouraging them to receive vaccination. The 
medical burden on the government and the productivity loss of society could be 
2 see Table 1 
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reduced. 
In this study, Prince of Wales Hospital (PWH) was chosen as the source of 
subjects. Data were obtained from two departments in the hospital. The case histories 
of CHB, CC and DC were obtained from the Department of Hepatology, while the 
data for HCC were obtained from the Department of Oncology. 
The study can be divided into two parts. The first part involves the calculation 
of the average monthly medical expenses per patient from government's perspective. 
Items taken into calculation include: outpatient medical care visit, radiology, 
inpatient care, medications, antiviral, organ imaging, operations, chemotherapy, 
selective internal radiation (SIR) and blood transfusion. All the investigative 
procedures and treatments in the case history were from the day the patients 
diagnosed to be one of the four HB-related health states through December 2001 
would be taken into account. The unit costs were obtained from references lists of the 
government and the PWH for 2001. 
The second part involves the calculation of the average annual productivity loss 
per patient due to HB-related diseases from a societal perspective. Taken into 
consideration are: outpatient medical care visits, inpatient care and radiology. Being 
carriers of HBV, patients had to pay regular visits to hospitals for investigation and 
for different types of treatment. It is clear that they lost work time in the process. The 
4 
longer was the infection and the course of therapy, or the more serious the condition, 
the longer would be the time lost for work, and eventually the greater would be the 
loss to society. Thus, another aim of this study is to calculate the IMC caused by the 
disease. The average annual number of workdays lost by the patient were starting 
from their first visit to the hospital through December 2001 would be included in 
the calculation. The IMC will be measured based on the GDP per capita in 2001. 
Another type of IMC that is worth considering arises for patients with HCC. 
Under the threat of this fatal disease, patients risk premature death. In some cases, 
they die prior to those dying from the natural death, losing the working time from 
premature death to normal retirement age, thus leading to economic loss in society. 
As a result, productivity loss from premature death should also be estimated. 
Moreover, it would be nice to see some cost statistics adjusted for patient 
characteristics like age, gender, comorbidities and fatality by using ANOVA or 
regression analysis. However, there are limitations so. For age, before using this 
attribute to run the regression, we need to break it down into different age brackets, 
but this is very subjective. Also, there is no medical evidence showing that gender is 
an important factor in the HB-related diseases. In other words, male or female have 
the same chances of being infected with HB-related diseases. Lastly, the sample size 
didn't contain the information of comorbidities and fatality, so we can't use these two 
5 
attributes to run the regression. 
In short, the study mainly focuses on these two objectives with an aim to obtain 
insights into HB-related diseases. 
6 
Chapter 2: Research Background 
2.1 Epidemiology of Hepatitis B Virus (HBV) 
HBV is a mostly double-stranded DNA vims in the Hepatnaviridae family. 
(Poynard. T. 2002) The HBV genome has four genesipol, env, pre-core and X that 
respectively encode the viral DNA-polymerase, envelope protein, pre-core 
protein(which is processed to viral capsid)and protein X. The function of protein X is 
not clear but it may be involved in the activation of host cell genes and the 
development of cancer. (Grisolia and Felipo 1993) 
Risk Factors for HBV infection 
Although relatively rare in the United States, hepatitis B is endemic in parts of 
Asia where hundreds of millions of individuals may be infected. Blood and blood 
products and sexual transmission transmit HBV horizontally. And it can also transmit 
vertically from mother to infant in the perinatal period, which is a major mode of 
transmission in regions where hepatitis B is endemic. 
At present transmission by blood transfusion is extremely rare, the major routes 
of transmission among adults in Western Countries are through intravenous drug use 
and sexual contact. The risk of HBV infection is extremely high in promiscuous 
homosexual men but it can also transmitted sexually from men to women and women 
to men. The increased risk of infection is in the group of health care workers even 
7 
they have received hem dialysis beforehand. 
Effective vaccines are available for the prevention of HBV infection. All 
individuals at risk for infection should be vaccinated. Post-exposure prophylaxis with 
hepatitis B immune globulin is also effective for non-immune individuals after a 
known exposure. 
Symptoms 
Many people with hepatitis B have no symptoms. They don't know they have it 
useless they get a blood test. But even with no symptoms, they can still become 
carriers. 
According to the website (http://www.epmcnet/Columbia.edu/dept/gi/hep.htm), 
more than half of patients with uncomplicated CHB have no symptoms of liver 
disease. The most common symptom is fatigue, which is generally mild and 
intermittent, rarely interfering with work but worsened by exertion or intense 
exercise. Less frequent symptoms include nausea, poor appetite, abdominal pain, 
weight loss, and dark urine. All symptoms tend to worsen with exertion. Symptoms 
of immune complex disposition such as myalgias, arthralgias, and transient rashes 
can also occur and are particularly common in women. Symptoms of correlate poorly 
with the activity of the liver disease and the serum aminotransferase activities, but 
some correlation may be found in an individual patient. Symptoms of liver disease 
8 
generally become more common and troublesome when cirrhosis develops. Patients 
may have persistent fatigue, inability to work, weakness, nausea, poor appetite, 
weight loss, wasting, abdominal swelling, edema, itching, dark urine, and jaundice. 
Consequences of HBV infection 
HBV causes acute and chronic hepatitis. The chance of becoming chronically 
infected depends upon age. According to the website stated previously, about 90% of 
infected neonates and 50% of infected young children will become chronically 
infected. In contrast, only about 5% to 10% of immunocompetent adults infected 
with HBV develop CHB. In some individuals who become chronically infected, 
especially neonates and children, acute infection will not be clinically apparent. 
The natural history of CHB can vary dramatically between individuals. Some 
will develop a condition commonly referred to as a chronic carrier state and some 
other patients, who are still potentially infectious, have no symptoms and no 
abnormalities in laboratory testing. Nonetheless, in a liver biopsy, some of these 
patients will have evidence shown of hepatitis. 
Some individuals with CHB will have clinically insignificant or minimal liver 
disease and never develop complications. Others will have clinically apparent CHB. 
Some will go on to develop cirrhosis. Individuals with CHB, especially those with 
cirrhosis are at an increased risk of developing HCC. It is the leading cause of cancer 
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death in the world, especially in those endemic areas. 
According to Poynard. T. (2002), chronic infection with HBV can be mainly 
divided into either "replicative" or "non-replicative." In non-replicative infection, the 
rate of viral replication in the liver is low and serum HBV DNA concentration is 
generally low and hepatitis B antigen (HBsAg) is not detected. HBeAg is an 
alternatively processed protein of the pre-core gene that is not only synthesized under 
conditions of high viral replication. In "replicative" infection, the patient usually has 
a relatively high serum concentration of viral DNA and detectable HBeAg. Patients 
with CHB and "replicative"infection defined by the presence of detectable HBeAg 
have a generally worse prognosis and a greater chance of developing cirrhosis and or 
HCC than those without HBeAg. In rare strains of HBV with mutations in the 
pre-core gene, “replicative’’ infection can occur in the absence of detectable serum 
HBeAg. 
Diagnosis 
According to Totowa, N.J (2002) The diagnosis of HBV infection is generally 
made on the basis of serology. Virtually all individuals infected with HBV, either 
acutely or chronically, will have detectable serum HB surface antigen (HBsAg). 
Diagnosis of HB is confirmed, and prognosis is usually assessed by liver biopsy. 
Most people who are chronic carriers generally have little or no inflammation on 
10 
biopsy. In such patients, there are "ground glass cells" on liver biopsy which are liver 
cells in which large amounts of HBsAg is being synthesized. Other individuals with 
CHB will have various degrees of liver inflammation on biopsy. Others will have 
fibrosis or cirrhosis. The amounts of inflammation, and the presence of fibrosis or 
cirrhosis, correlate with a worse prognosis. 
Cancer Screening 
Individuals with CHB are at increased risk for the development of HCC. 
Although precise recommendations do not exist, it is reasonable for such individuals 
to undergo periodic screening for cancer. Screening procedures include measurement 
of serum alpha-fetoprotein and ultrasound examination. 
Treatment 
According to Leong (1999), alpha-interferons were the first drugs approved in 
the US for the treatment of CHB. Interferon treatment is recommended for 
individuals who have "replicative disease"(HBeAg positive). About 40% of such 
individuals will lose serum HBeAg after 16 weeks of treatment with interferon-alpha. 
A few treated patients may even be cured as assessed by the loss of HBsAg. 
Other promising treatment options of CHB include nucleoside analogues. In 
December 1998, according to United States Food and Drug Administration, it 
approved lamivudine for the treatment of CHB (patients who are HbeAg positive). 
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Lamivudine is taken orally at lOOmg/day for CHB. In studies where they were 
compared, lamivudine was equally effective to interferon-alpha in inducing a loss of 
serum HBeAg. It also has been shown to improve liver biopsy results in patients 
treated for one year. At the present time, other nucleoside analogues are being 
studied in clinical trials. The combination of interferon-alpha and a nucleodide 
analogue such as lamivudine is also under investigation. 
2.2 The prevalence of HBV around the world 
It is estimated that are three quarters of 350 million carriers of HBV are Asian. 
Male to female ratio is 6 to 1. The prevalence of HBV carriage varies among 
different regions. It ranges from 0.1-0.2% in Britain to 10-15% in Africa and Far 
East. More than 285 million people are chronic carriers of the vims, of who about 
75% are Asians. (Public Health Report 2001) 
The World Health Organization has classified the HB endemicity of the world's 
nations by the proportion of adult populations who are HB (Map 1) . The low 
prevalence areas, with less than 2% carriers, are the Americas, Western Europe and 
Australia, where adult transmission predominates. Intermediate levels of prevalence 
are found in Eastern and Southern Europe, in the Middle East, Japan and South Asia. 
3 see Appendix 3 
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The high prevalence areas (>8% carriers) are found in China, Southeast Asia and 
sub-Saharan Africa. Perinatal transmission is most important in Asia, accounting for 
30-40% of carriers, but less important in Africa, where only 5-10% of carriers are 
infected through this route. 
According to the website (http://www.hepb.0rg/c/hepbinfecti0n.html), high rates 
of HBV infection are apparent in Southeast Asia, Africa, the Pacific Islands and the 
Arctic. Most infections in these areas occur during childhood; consequently, there is 
a high carrier population. In areas of intermediate endemicity, such as Southern and 
Eastern Europe, and Central Asia, HBV transmission occurs across all age groups. 
Racial and socioeconomic differences contribute to variations in disease prevalence 
within these areas. Early childhood infection also appears responsible for 
maintenance of a substantial carrier population. In countries with low rates of 
infection HBV transmission occurs primarily among adults with high-risk 
occupations or lifestyles. Within these countries there are also groups of resident 
immigrants which have infection rates considerably higher than those in the general 
population and which demonstrate patterns of disease transmission similar to those 
seen in countries of high endemicity. 
The website (http://www.cdc.gov/ncidod/diseases/hepatitisb/fact.html), stated 
that parenteral drug users, homosexually active men, and heterosexual individuals 
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with multiple sexual partners represent the three largest groups at high risk for HBV 
infection, collectively accounting for 59% of reported cases. Other high-risk groups 
include health care personnel, blood transfusion recipients, heaemodialysis patients, 
household contracts of infected persons, and residents at institution for the 
developmentally disabled, although the contribution of these groups to total disease 
incidence is small (<10%). However, risk factors are not always present, and for 
those with not known risk factors account for 32% of cases (Alter et al. 1990; Kane 
et al. 1989). 
An important source of chronic infection results from transmission of HBV 
from HbsAg positive mothers to their newborn infants during the perinatal period. As 
the information provided by the website (http://www.globalserv.net/~har/equin/HBV), 
infants bom to mothers with high levels of circulating vims, indicated by a positive 
test for the hepatitis e antigen (HBeAg)，have a 70 to 90% risk of perinatal infection 
and an approximately 90% chance of developing carrier status after initial infection. 
A lower risk of perinatal infection (10 to 40%) and subsequent chronic infection (40 
to 70%)has been noted for infants of HBeAg negative mothers. In addition, those 
bom to HBsAg positive mothers who do not acquire infection at birth remain at high 
risk of infection through horizontal HBV transmission during the first five years of 
life (Margolis et al. 1991). 
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Evidence has been demonstrated in an ongoing prospective epidemiological 
study and at the molecular level that there are strong causal association between 
HBV infection and HCC.There is also a geographical correlation between carrier 
status prevalence and the incidence of HCC. HCC is one of the most common 
cancers worldwide, although it is relatively uncommon in most developed countries 
nowadays. 
Situation in US 
The Centers for Disease Control and Prevention (CDC) estimates that each year 
about 240,000 Americans gets HB. According to the website 
(http://www.epmcent/Columbia.edii/dept/gi/hep.html), HB vaccine available since 
1982, number of new infections per year has declined from an average of 450,000 in 
the 1980s to about 80,000 in 1999.Highest rate of disease occurs in 20-49 year olds, 
but the greatest decline has happened among children and adolescents due to routine 
HB vaccination .It found that chronic infection occurs in: 90% of infants infected at 
birth, 30% of children infected at age 1-5 years and 6% of persons infected after age 
years. Estimated 1.25 million chronically infected Americans, of whom 20-30% 
acquired their infection in childhood. 
Situation in China 
In China, the overall prevalence of HBsAg was 9.8%. The prevalence was 
15 
higher in males (11.3%) than in females (8.2%). Geographically the prevalence in 
southern China (10.8%)was higher than that in northern China (8.5%), and also 
higher in rural villages (10.5%) than in urban cities (8.1%). (Public Health Report, 
2001) 
2.3 The prevalence of HBV in Hong Kong 
HB is a public health problem in Hong Kong because of the high number of 
CHB. The HBV carrier rate in Hong Kong has been declining from 10% to about 
7-8% in the past 20 years. About 40% of the adults have been infected with HBV. 
One out of two persons in Hong Kong are susceptible to the disease. The rest are 
either chronic carriers (one in 10 people) or have been infected in the past, and have 
recovered. All non-infected members of the community are susceptible to HB 
infection/ amongst whom, five groups are high-risk individuals: The first group is 
the babies bom to infected carrier mothers. 90% of infected neonates go on to 
become carriers who are 200 times more likely to suffer from liver cancer than a 
non-carrier later in life. Also, for those persons receiving acupuncture treatment or 
who are having themselves tattooed and people who play contact sports and likely to 
suffer cuts and abrasions. The fourth group is sexually promiscuous youth, 
4 Hepatitis B Virus Carriers. Department of Health: 2001 
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homosexuals, prostitutes and the last group is the frequent travelers to highly 
endemic areas in the region, including China^. 
Health authority records show that currently more than 700,000 persons in 
Hong Kong are HB carriers. The HB carrier rate in Hong Kong has been declining 
from 10% to about 7-8% in the past 20 years. It found that 90-95% of adults would 
recover and HBsAg usually disappears within 4-6 weeks. However, about 5-10% of 
adult patients will become chronic carriers. Up to 25% of them may be complicated 
with cirrhosis or liver cancer. The rest are healthy carriers. The HBV's male to 
female ratio is about 6:1 and for the HCC's male to female ratio is 4:1.For cirrhosis, 
it occurs in a calculated annual rate of 2.4% and 1.3% in HBeAg positive and 
anti-HBe positive patients respectively. Those HBsAg carriers acquired perinatally 
have an annual probability of developing liver cancer of 0.49% per yeaA 
2.4 Standard medical treatment 
The Hospital Authority has not developed a standard medical care system for 
patients having CHB, CC, DC or HCC in Hong Kong. However, through recording 
numerous medical case histories, the exact treatments presented to patients can be 
observed. 
5 Know more about HBV. ASIAHEP Hong Kong:2001 
6 http://www.cuhk.edu.hk/proj/hep/asiahep.htm 
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If doctors suspected patients to be HB carriers, a series of laboratory tests, 
including common ALT, AFP and HB markers?, would be carried out. ALT and AFP 
are adopted to monitor the protein condition in the liver. HB markers are used to 
determine whether a patient is infected with the HBV and the level of liver damage. 
Generally speaking, HBsAg and HBeAg test are used for screening patients' liver for 
HBV infection and to detect actively replicating viral infections in liver. And HBeAb 
is used to test whether a patient can produce enough antigens against the vims. If 
antigen could not be found in his or her body for six consecutive months, he or she 
would then be regarded as CHB. For these CHB patients, regular outpatient visits are 
arranged. A series of laboratory tests are undertaken during each visit. When 
necessary, medications are given to replenish vitamin K loss resulted from liver 
damage. The doctors also arrange ultrasonography (USG) investigation to monitor 
the patients' situation. To get a clearer picture of the condition of liver damage, 
inpatient visit may be required so that liver biopsy can be carried out. 
If patients were found suitable after investigation, antiviral treatment would be 
adopted. Interferon and lamivudine are the two most effective antiviral nowadays. 
The duration of therapy is very long, lasting for at least 24 weeks. The side effects 
are serious. Since HB disease is irreversible, even antiviral can only slow down the 
7 Including HBsAg, HBeAg and HBeAb 
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reproduction rate of the virus, resulting in sero-conversion at most. 
Many complications develop from HB-related disease. Some common examples 
are jaundice, ascites, spider angioma, variceal bleeding and hepatic encephalopathy. 
A patient would be transferred from the Department of Hepatology to the 
Oncology for treatments after the health state had been deteriorated and suspected of 
HCC. For early HCC patients, doctors often advise them to receive operation to 
remove the tumor, or receive selective internal radiation (SIR) treatment. If the 
disease reached a late stage, usually chemotherapy would be adopted. 
During the treatments, various investigation methods are used to monitor 
patients' health condition. Some common methods include: CT scan, MRI and 
hepatic angiogram. Serious patients even need to receive treatments like abdominal 
tapping and blood transfusion. 
All the above treatments were commonly found when recording the medical 
case histories. 
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Chapter 3:Literature Review 
Hepatitis B virus (HBV) is the world's most common blood-bome viral 
infection, chronically infecting more than 350 million people worldwide. (World 
Health Report, 2000) It is responsible for substantial morbidity and mortality and is a 
leading cause of HCC. Approximately 300,000 Americans are infected with HBV 
each year, with an annual incidence rate of 11.5/10,000 populations. Serologic 
evidence of previous infection is found in 4.8% of the U.S. population. Each year 
approximately 4,000 persons in the United States die of HB-related cirrhosis and 
about 800 people die of HB-related HCC. (World Health Report, 2000) Despite the 
widespread distribution of HBV infection and the ongoing controversy about HBV 
immunization, surprisingly, few published studies examined in detail the economic 
impact of HBV infection. Its severity arouses the public concern and so starting from 
1980, there attracted numerous studies to describe the picture of this story. 
The fundamental question, which is the main concern of this thesis, is the cost 
of CHB and the social and economic burden to society. HBV infection places an 
economic burden on society, not only because it may manifest as both acute and 
chronic illness and is associated with high morbidity, but also because there is no 
effective treatment. Furthermore, HBV infection during early childhood may result in 
mortality after the second or third decade of life. The death of an economically 
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productive adult may have substantial economic implications form both societal and 
familial perspectives. Indeed, because active HBV infection occurs most commonly 
in those who are economically active, indirect costs associated with overall cost of 
disease. However, the value of lost work time will vary depending on the level of 
unemployment and underemployment in a country. 
The aim of this study is to calculate the government medical burden and the 
working productivity loss of society for four health states evolved by HBV, namely 
chronic hepatitis B, compensated cirrhosis, decompensated cirrhosis and 
hepatocellular carcinoma. 
Study type 
Cost of illness is typically estimated using either incidence or prevalence-based 
models. Incidence-based models include costs incurred from onset of disease until 
cure or death, while prevalence-based models include costs incurred during a 
specified period of time, always one year. Because of the long term course of HBV 
infection and its sequelae, an incidence-based model is the most appropriate 
methodology for estimating the costs associated with CHB infection. In an 
incidence-based analysis (Chan et al 2001;Metcalf et al 1999; Margolis et al 1995), 
the studies studied the direct medical costs and indirect costs for the HBV infection 
over the different period of time. But all of these figures probably undervalue the 
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cost of disease, as conservative estimates were applied. 
A prevalence-based analysis of the economic burden of HBV-related liver 
disease in the South Korea (Yang et al 2001), it describes the more comprehensive 
picture of acute and chronic carrier, cirrhosis and liver cancer. It estimated the 
prevention cost, direct cost and indirect cost of each patient group. Once infected 
HBV, it will likely progress into different health states during the lifetime including 
CHB, cirrhosis and HCC. The economic analyses of estimating the direct and 
indirect costs of different patient groups have been studied (Margolis et al 1995; 
Chan et al 2001;Yang et al 2001) but mainly, most previous studies estimated the 
direct cost of CHB carriers (Metcalf et al 1999). Numerous methods are used for the 
calculation. 
Yang et al (2001) has a more comprehensive study not only to the direct costs, 
but also the indirect costs. This study used the societal perspective to account for the 
direct and indirect cost of prevention costs, treatment costs and disease costs of acute 
and chronic hepatitis, cirrhosis and liver cancer. It estimated the total annual cost of 
HBV infection in South Korea in 1997.The costs summarized in the study was 
mainly in two areas including the preventive programs and medical services that 
patients receive for HBV related complications. It also calculated both the direct and 
indirect costs in these two areas. National Health Insurance (NHI) and the 
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questionnaire was the source to estimate the direct and indirect costs. The total 
societal cost of HBV in 1997 was 1,078.3 billion Won (US959.7 million), and most 
importantly, it found that the indirect costs (20.9%)attributable to a greater 
proportion to the total societal cost than the prevention cost (13.2%). On the other 
hand, the indirect cost adopted a pragmatic and conservative approach to estimate it. 
The costs included are the transportation (including the cost of the associated 
traveling time), reduced work productivity and premature death (i.e. productivity 
losses). Direct medical costs were (710,502 million Won) still nearly three fold 
higher than the indirect medical costs (225,575 million Won), but it was higher than 
the prevention costs (142,239 million Won). The results may be due to the reason 
that the assessment of indirect costs was incomplete thus accounting for the lower 
indirect cost component. To the best of my knowledge, this is the first study to 
attempt to determine the societal costs of HBV infection. The only defects was it did 
not include the opportunity cost of the term taken by relatives to care for HBV 
patients at home, while only those patients who died aged less than 55 years were 
included in the calculation of productivity losses. 
Metcalf et al (1999) did a retrospective case-control study to compare the 
patients with laboratory markers for CHB and with those patients without markers 
for CHB of direct medical costs.88 patients after identified as CHB would be 
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matched up to four control patients, so there were 342 patients being matched. 
Patients' information was extracted from a computerized database on 400,000 
patients enrolled in a large group model HMO in the northwestern United States. All 
the cost data for CHB and the corresponding control patients were collected during 
the period from January 1989 through December 1994. This study specified the time 
frame into three windows as follows: prediagnosis is 30 days before identification of 
the first marker of chronic hepatitis B, the second window was perdiagnosis (30 days 
before identification of the first marker through 180 days after the identification), and 
the third window was postdiagnosis (181 days after identification of the first marker 
through December 31,1994). The direct medical costs were classified as emergency 
room, inpatient care (extended hospital stay), short-stay inpatient (e.g., day surgery), 
laboratory, radiology, office visit, pharmacy, outside claim, or other (e.g., physical 
therapy), all of these costs items were calculated in the following three windows 
stated: prediagnosis, peridiagnosis and postdiagnosis.Costs were analyzed as ratios of 
the costs of each patient with CHB to the median of the corresponding control 
patients. After this, these ratios were logarithmically transformed, and the mean of 
the logarithmic values for all patients with CHB was also calculated. Finally, the 
three ratios for the group of patients with CHB as a whole were calculated by 
computing the antilog of each mean. Logarithmic transformations were performed to 
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see whether it was skewed distributions a theoretical mean of zero. The Wilcoxon 
signed-rank test was then used to determine whether the distribution of the 
logarithmically transformed ratios was centered on zero. The results concluded as 
follows: before the appearance of a diagnostic marker, aggregate costs for patients 
with CHB were similar to those for control patients. The patients with CHB had costs 
3.3 times than those of the corresponding control patients in the seven months 
starting from the appearance of their first diagnostic marker, 2.9 times those of the 
control patients per month after the first seven months. The control patients were 
significantly lower for patients with CHB in the window of peridiagnosis in the 
categories of laboratory, radiology, office visits, and pharmacy. The major drawback 
is: it could be argued that those two groups of patients were co-infected with the 
other diseases and therefore affected the accuracy of the costs being calculated. 
Margolis et al (1995) estimated the direct and indirect medical costs for the 
person with CHB. The study used both retrospective and prospective approach to see 
whether there are any differences between the childhoods and adult infections. The 
patient groups under study were acute and chronic HBV infection and the direct 
medical costs were obtained from published data and those data were adjusted to 
1993 dollars using the medical care component of the consumer price index. Medical 
costs were estimated to have occurred for the above patient groups over a 10-year 
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period and concentrated in the final 5 years of the illness, except for those patients 
who were with primary hepatocellular carcinoma alone where costs occurred in the 
year of 1994.The underlying assumptions of the study was that 50 percent of chronic 
carriers progressed to cirrhosis during the last 5 years of life, and that 50 percent of 
patients with primary hepatocellular carcinoma had expenses associated with 
cirrhosis. It found that the median age at death was estimated to be 45 years for 
persons infected as infants or young children and 55 years for those infected as 
adoledscents or adults. Nevertheless, the true cost of disease was appeared to under 
valued. This is because direct medical costs did not include expenditure associated 
with outpatient management of HB-related chronic liver disease, while indirect costs 
included only lost work time due to active disease. With an accurate estimation, the 
indirect costs should include loss of earnings due to illness, medical care visits, or 
pre-mature mortality. In this study, estimates of diagnosis-specific annual number of 
hospitalizations and outpatient visits were derived from the literature and from a 
population based study of the incidence, prevalence, and outcome of chronic liver 
diseases. The above calculation assumed that persons were productively employed 
between the ages of 20 to 65 years, and after adjusting for the unemployment, the 
average lifetime earnings would be estimated from current sources, and included a 1 
percent annual increase in productivity. Furthermore, disease mortality was 
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accounted for the productivity losses in the analysis included the lost of work time, 
however, no assessment was made to measure indirect costs like patient 
transportation expenses and the cost of home care. Inclusion of these parameters 
would increase the contribution of indirect costs to the total cost of the disease. 
There are relatively few studies about the direct and indirect costs of HCC's 
patients. A recent study in Hong Kong (Chan et al 2001) was a societal perspective 
including formal and informal costs incurred by payers, caregivers and patients. All 
patients with HCC who presented to the Department of Clinical Oncology, Prince of 
Wales Hospital during the period from June 1996 to May 1997 were under analysis 
in this study. Direct medical costs included short term inpatient hospital care, 
continuing inpatient care and hospice care, outpatient services like clinics, diagnostic 
tests, and drugs, Chinese and herbal medicines, supplies privately obtained, and the 
income lost by caregivers and patients. It found the direct medical costs and indirect 
costs was HK$31,252 HK$27,821 per person respectively. The window of study 
used 204 patients with inoperable HCC who were prospectively tracked from first 
hospitalization until death for health service utilization. Comparably, the direct 
economic burden will not be as high as the CHB carrier in the short survival period 
like the median survival was only 95 days. Questionnaires were used to capture the 
informal services and indirect costs were measured. Respondents in the personal 
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interview were directly contacted and were requested to estimate the informal 
healthcare resources, including both the amount spent for Chinese and herbal 
medicines, supplies related to their illness, and the loss of income from work not 
only the patients but also for care givers. It found that 93 persons incurred transport 
costs, at a mean value of HK$ 1,168. In addition, 10 patients incurred costs for 
Chinese herbal medicines and 28 incurred other healthcare costs at a mean value of 
HK$ 10,795 and HK$6,210 respectively. There are 62 patients and 11 caregivers 
reported a loss of income with a mean value of HK$83,734 and HK$8,500 with 
regard to indirect costs during the observation period. Lastly, the mean value per 
person for healthcare system costs was HK$30,983. However, assessment of indirect 
costs was incomplete thus accounting for the lower indirect cost component. In this 
study the cost of premature death and resulting productivity loss were not considered. 
These kinds of indirect costs are a serious economic burden to the whole society, but 
were not included in the analysis. 
Cost of different group 
Few economic analyses of HB-related diseases that estimated all the patients 
groups in their study, the prevalence-based study of Yang et al (2001) took acute and 
chronic hepatitis, cirrhosis and liver cancer into account. The total societal costs 
included the prevention costs, diseases-related treatment and indirect costs of HBV 
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related diseases were calculated. Previous studies (Margolis et al 1995;Metcalf et al 
1999; Harris,Yong and Kermode 2000; Fendrick et al 1999; Chan et al 2001) only 
concentrated on one group of patients and take the direct and indirect costs into 
account. Based on this study, Yang et al found that cirrhosis was the predominant 
cost driver among HB-related diseases, accounting for 50% of all direct costs. This is 
attributable not only to a large number of cirrhosis patients in both inpatient and 
outpatient categories, but also to the intensity of services used by such patients. 
Indeed, with the disease progression, the mean duration of hospital stay ranging form 
15 days for acute hepatitis to 39 days for liver cancer. Criticism of Yang et al's 
dataset falls under it only used the National Health Insurance database which only 
contained information regarding claims for reimbursed medical services, according 
to diagnosis. The sample bias will exist for those patients who didn't reimburse of its 
illness. 
These cost-of illness data provide some measure of the substantial economic 
burden of HBV infection including the lower productivity, higher unemployment. 
However, for those countries with limited healthcare resources means that the cost 
per patient may in fact be lower. Clearly, there is need for further study the countries 
of high endemic to quantify the total cost of HBV disease more accurately; in 
particular, the contribution of indirect costs, and the cost of HB-related illness. 
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Estimates of incidence costs of illness involve forecasting future costs. Thus, it 
is important to consider the change in the medical cost from the impact of changes in 
technology occurring in the future. Many of the complications of HBV infection 
manifest decades after initial infection, therapeutic and diagnostic standards of care 
and their potential costs were difficult to accurately predict in the future time. It is 
not surprising then, that none of the reviewed analyses specifically accounted for the 
effects of technological change on the costs of treatment. Some economic analyses, 
although it is difficult, it did include the cost of recent treatment innovations 
including liver transplantation (Ginsberg et al. 1992; Krahn and Detsky 1993) and 
interferon-alpha treatment (Demicheli & Jefferson 1992). However, interferon-alpha 
therapy and liver transplantation are expensive and generally have low success rates 
(Sherlock and Dooley 1993); consequently, they represent an increase in total 
treatment costs. Since most economic analyses probably underestimate the cost 
effectiveness of the vaccine because it did not take hepatitis B vaccine into 
consideration recent and future innovations in treatment. 
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Chapter 4: Data Compilation 
4.1 Prince of Wales Hospital's Dataset 
The medical history of a sample of 194 from Hepatology and 59 from Oncology 
patients were investigated in this retrospective study. For each patient in the sample, 
the window of investigation starts from the first day the patient was tested positive 
for diagnosing HB-related diseases through a period until December 2001. Within 
the study window, patients' medical history was studied in details. The hospital was 
chosen because it is a government-funded hospital that serves the Shatin district, 
which has more than 600,000 residents, in Hong Kong. It is also the teaching hospital 
affiliated to CUHK. To compile the sample for the present study, a physician was 
assigned to shortlist the relevant patient group, amounting to 194 patients in 
Hepatology and 59 patients in Oncology. 
Outpatient care was based on clinic visits, pharmaceuticals, and diagnostic 
services in Specialist clinics. Outpatient clinic costs and the inpatients care costs, 
including nursing and physician costs, were based on the price published by the 
PWH. The cost of outpatient drugs was based on the formulary cost at the PWH. 
Diagnostic services were valued in terms of workload units. 
A well-developed computer system for keeping the patients' medical case 
history is still lacking in the PWH. Finding out the details about the diagnosis, 
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investigation and treatment received by the patients in various health states is a tough 
task. Therefore, to give an accurate indication of the patients health condition in 
different health states, the most traditional way was adopted - the use of medical 
o 
case history's hard copies . 
Usually, a medical case history consists of the following basic parts: First，when 
a patient treated in different departments, the doctors in charge would record the 
patient's health condition, symptoms, treatments arranged, medications and 
follow-up time in hand writing. The second is the inpatient record. Similar to the first 
part, the doctors would record the patient's health condition during hospital stays and 
other information such as diagnosis, medications, operations and blood transfusion in 
hand writing. In the case history, there are several folders, including the laboratory 
test results, X-Ray provided by the Department of Radiology, USG, CT scan, 
investigation report of MRI, and the investigation report of hepatic angiogram 
provided by the Department of Diagnostic and Organ Imaging. Besides, if the patient 
received any clinical trial, detailed records on diagnosis and treatment as well as 
effectiveness can be found also. If the patient need to undergo any treatment in the 
8 Yet, due to the Personal Data (Privacy) Ordinance, it is rather difficult to borrow the patients' 
records. To protect the rights of these patients, much time was spent on the complex administration 
procedure. In addition, the copies borrowed cannot be read outside the hospital. So during the study, 
daily visits to the hospital for these reference materials were needed. 
In fact, medical case histories are the record of patients. All the treatments the patients received in the 
hospital were recorded. For instance, a patient may undergo treatments from several departments like 
Orthopedic, Pediatric, Surgical and Intensive Unit Care simultaneously. Thus sorting out the required 
information for this study is really a challenge. 
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Department of Oncology, the case history can then be divided into more smaller 
parts - chemotherapy, about which the duration, the dosage of medications, patient's 
response and effectiveness were recorded, SIR, about which details were recorded, 
and operation, about which the health condition of patients, the effectiveness and the 
diagnosis of the doctors were described clearly. 
Apart from a general grasp about the information in the case history, before 
recording every investigation and treatment, it is necessary to know clearly the 
details, usages and treatments of every item so as to make appropriate selection. Take 
laboratory test as an example. When making record, the aim of the test must be 
clearly understood^. For ALT, AST, AFP, HB markers, they are used to test the health 
condition of liver directly. The aim of other tests such as PT/APTT, CBP and DNA 
tests is to monitor the patient's health condition after receiving medications during 
treatments like antiviral. Similarly, for medications, the dosage, frequency and 
patterns of medications have to be familiarized. Otherwise, the medications for other 
diseases may be calculated wrongly in the present study. Attention must be paid 
particularly to HCC patients. As their health problem is very serious, many 
complications developed. The medication types can be tenfold that of CHB and 
cirrhosis patients. In the calculation of their medical costs, therefore, both direct 
9 Appendix 1 
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medication and indirect medication^® for treating the complications were included so 
that these patients' medical expenses can be calculated accurately. Furthermore, 
knowing the content of the medical report of investigation is a must. In a medical 
report, there are USG, liver biopsy, CT scan, hepatic angiogram, MRJ, outpatient and 
inpatient care's medical report. Information on the treatment times a patient received 
and whether the patient progressed to other health states after the treatments are 
provided. When studying HCC patients, apart from the above information, other 
information like SIR, resection and chemotherapy, blood transfusion, packed cells 
and platelets, abdominal tapping or paracentersis and oesoplagogastrodenscopy with 
biopsy (OGD biopsy), need to be noted for accurate calculation of the patient's 
medical expenses. In short, learning the background, prevalence and epidemiology of 
the disease, medication, investigation and treatment objectives and results is the 
prerequisites for accurate calculation of the cost involved in the study before starting 
to make records. 
Sorting out the required medical information of all patients in the study group is 
not enough. After recording, the unit medical costs involved in the investigation and 
treatment needs to be found. Despite the medical costs the government and the PWH 
published yearly, the information is sporadic rather than centralized. The departments 
10 It defined as: the patients may suffer from the complications caused by HB related diseases, so they 
might need to drink some other medicine to cure for them, for that part of medications (not directly 
cure for the liver), the study estimates it in a separate item called indirect medication. 
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only know the costs of the items they provide. So to get information about the cost 
items, inquiry must be made to related departments, including Pathology, Oncology, 
Accounting, Surgical, Pharmacy, Radiology, Diagnostic & Organ Imaging 
departments, involving complicated administrative procedures. 
After obtaining patients' raw data from Hepatology and Oncology, the 
calculations of medical expenses need to start from government's perspective. There 
are three sources of cost data used to do the calculation. The first is the gazetted rate 
published by the government. Hospital Authority (HA) provided the second source 
of cost data. And the last source is if we found that some of the cost data which 
cannot be extracted from either the government or the HA, then the cost items of 
private cases in public hospitals are used instead�� As for the particular source of 
particular cost item, one can refer to the following: 
Table (2，2.1, 2.2, 2.3) 
4.2 Expert Opinion and other published data 
A panel of experts (hepatologists, pharmacists and economists) was consulted to 
identify the places where patients seek treatment and all the epidemiology about the 
illness.Whenever possible, published data on Hong Kong studies and population 
statistics published by the Department of Health, Red Cross, Hospital Authority and 
11 Public hospitals are non-profit making and so the charges for private cases are in fact close to cost. 
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Statistical Department were used to gain a better understanding of HBV in terms of 
its epidemiology and disease progression. 
The subjects of this study are patients suffering CHB. As time passed by, their 
health condition may worsen with gradual progression to CC, DC and HCC. 
Therefore, patients from all these four groups are our study targets. Without a 
well-developed and comprehensive computer system for keeping the patients' 
records in Hong Kong, it is not hard to understand the difficulty in carrying out 
research in this field. No wonder the study and calculation of the medical expenses of 
HB-related disease in Hong Kong, or even other advanced countries are so limited. 
4.3 Definition of health states under study ^^  
In this study, four health states are defined using criteria described below. 
Figure 1 
Chronic HBV: 
HBV, if persists for more than six months, is defined as chronic hepatitis. Adults 
infected with HBV for the first time are usually able to get rid of the virus after six 
months. If the vims remains in the blood after six months，then the patient can be 
diagnosed as a CHB. This means the patient can pass the virus on to others. He/she is 
i2This part of information comes from the following website : http://www.bmshepb.com/wc.dll? 
mru�main ； http://www.info.gov.hk/dh ； http://www.info.gov.hk/hepatitis 
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also at greater risk for developing serious liver disease later in life. If the patient is a 
pregnant woman, she could also pass the virus on to her newborn baby. 
HB causes no symptoms at all in about 50 percent of cases. The majority of 
patients are asymptomatic but liver enzymes are elevated. CHB can be diagnosed via 
four different ways, namely the liver biopsy, USG, liver function test (comprising 
three main laboratory tests like ALT, AFP and AST) and serological tests. 
Cirrhosis: 
Patients who progress to cirrhosis are initially asymptomatic, but have a high 
probability over time of death from liver failure and an increased risk of hepatoma. 
Those who do not develop liver failure or hepatoma remain in the cirrhosis health 
state or die from causes unrelated to HBV infection. Cirrhosis consists of fibrosis of 
the hepatic parenchyma resulting in nodule formation. It represents the consequences 
of a sustained wound-healing response to chronic liver injury. For operational 
purpose, this study adopts the follow criteria in the classification of CC and DC. 
1. Compensated Cirrhosis 
Patients with HB and CC (but no complications such as variceal bleeds, 
ascites, or hepatic encephalopathy), it will be diagnosed as CC. These patients 
could be identified through clinical signs such as jaundice, spider angiomas, or 
gynecomastia. 
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2. Decompensated Cirrhosis 
DC is defined as a patient with one or more of the following complications: 
variceal bleeding, hepatic encephalopathy, or ascites. Patients with DC may 
show one or more of the above symptoms. 
Hepatocellular carcinoma 
It is referring to the primary invasive tumor of the liver Alpha-fetoprotein (AFP) 
screening has been adopted in clinical settings to detect asymptomatic or subclinical 
HCC. However, the use of AFP screening as a public health measure has many 
limitations. A cost-effective screening programme should satisfy the criteria 
proposed by Wilson and Jungner/^ Those HCC's patients are asymptomatic at the 
early stage, followed by the signs and symptoms of anorexia，low-grade fever, right 
upper quadrant pain and distention. Some patients may start to lose body weight and 
feel distended abdomen, jaundice and deranged liver function are the late stage 
symptoms. The patients at this stage will be investigated to see whether they are 
operable or not, if not, then special treatment will be tried including chemotherapy 
and selective internal radiation. 
Appendix 2 
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Chapter 5: Empirical Findings I 
5.1 Estimation of disease costs from Department of Hepatology 
DMC for the following diseases states were estimated: CHB, CC, DC and HCC, 
based on the number of patients seeking treatments under the respective medical case 
history in the PWH. 
5.1.1 Methodology and sample size 
In the present study, we adopted a pragmatic approach in which various 
methods were used to calculate the different medical cost aspects of HB-related 
diseases in Hong Kong. In total, 194 patients (CHB, n二 186; CC, n=76; DC, n=6) all 
came from the Department of Hepatology of the PWH. All patients have a 
continuous medical history at PWH from the first day till December 2001. The 
time frame follows within the period from 1985 to 2001. During this period, as time 
passed by, the patient might progress from one health state to another. If this were the 
case, then the day of diagnosis of such progress would be taken as the last day of the 
previous health state and the first day of the following health state. And the average 
monthly DMC per patient of the health states would be calculated accordingly. 
During the study period that runs from the first day of a patient's treatment 
through ist December 2001, all the health states of the patient were taken into the 
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calculation for the average monthly DMC per patient from government's perspective, 
so that the economic burden posed by HBV on government's medical expenditure 
can be estimated. 
From a societal point of view, such information is useful for resource allocation, 
priority setting and determining future health policies. 
One interesting aspect of cost studies is the presence of co-existing diseases. 
Very few early studies made allowance for such co-existence. The costs arisen from a 
HB-related patient may not be entirely attributable to the HB-related disease. If a HB 
patient also contracted other diseases, then the DMC identified from the case history 
of this patient would be an overestimate of the true cost of the diseases. Therefore, an 
attempt was made to differentiate among three cost categories in this study. 
1. HB-related costs. 
2. Joint costs (costs not exclusively attributable to any single disease, CHB or 
otherwise). 
3. Non-HB-related costs or cost of co-existing diseases. 
A clear distinction of the three types of cost allows for a more precise estimate of 
the cost of HB. 
As mentioned in the section about literature review, very often a patient may 
suffer from several types of diseases at a time. For instance, diabetes, hypertension 
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and CHB can all be found in a patient. In this case, when giving diagnosis, 
investigation and treatment, doctors tend not to record the details separately for each 
disease. All the information was put together in the case history. So ambiguous 
knowledge about the treatment items may lead to overestimation of the medical 
expenses of a patient with co-existing diseases. In the US and other European 
countries with large-scale medical insurance system, when found sick, patients will 
claim all the medical expenses from the insurance companies. Added to this is the 
possession of well-developed computer systems for records. These make the 
calculation of medical cost a lot easier. Yet, using the information from these sources 
is not without potential problem. The medical expenses of a patient suffering from 
co-existing diseases may be overestimated, as explained above, if merely the 
economic burden caused by CHB is required. In this study, however, the problem can 
be avoided because the records were read through manually. Take a patient with both 
CHB and diabetes as an example. For the patient, ALT test is one of the laboratory 
tests that are always need to do during the outpatient visit . Had the case history not 
recorded manually; such medical cost may be included or excluded by mistake from 
the calculation. Another example is that when the health of a CHB patient 
deteriorated and progressed to the health state DC or even HCC, more complications 
developed. In the study group, hepatic encephalopathy, neuropsychiatric disorder, 
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occurred in one of the patients. Therefore, the patient also received psychiatric 
treatment and medication. If the reasons why the patient had to receive these 
medications were not considered, probably the related medical costs would be 
excluded in the calculation. Unlike similar research conducted in European or 
American countries, a strong point of this study is that the three cost categories 
mentioned earlier can be classified more accurately. Undoubtedly, it is easy to 
distinguish between categories (1) and category (3)，while for category (2), grey 
areas exist even when case history manual recording is adopted. Although it is 
impossible to eliminate these kinds of limitation, the accuracy of in the calculation of 
medical expenses has already largely increased. Actually, medication is the most 
complicated part to classify. Fortunately, its costs just account for a minor portion in 
the DMC. Even if the cost of this part is classified wrongly; impact on the overall 
study is not too serious. 
5.1.2 Summary of costs included in the analysis 
HB related annual costs are incurred in two distinct areas: DMC and IMC that 
patients receive for HB-related diseases. 
Direct medical costs 
DMC, which include the cost of medical services, are incurred in several areas. 
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Initially, all patients have their disease status and liver function determined by 
consultation with a Western-type medical physician. After this, the majority of 
patients will opt to continue to receive medical treatment from Western-type 
medicine providers. A small minority of patients will seek alternative treatment from 
herbal medicine providers. In addition, laboratory test, medication, inpatient care, 
antiviral are included in the calculation. For the IMC's part, it is discussed in the later 
chapter. 
5.1.3 Descriptive Analysis 
Hepatology provides medical treatment for the patients of CHB, CC and DC. In 
the calculation process of medical expenses, the costs to these patients at the stage of 
CHB were calculated. During the study period, if a patient progressed from CHB to 
other states like CC or DC, the costs were then calculated as the medical expenses of 
another health state. Thus, these three subgroups were analyzed together for 
background information. 
Table 3，Figure (2，2.1, 2.2) 
194 patients were recruited and their characteristics are listed in Table 3. In the 
study group, the mean age is 38.4. 135 are male while 59 are female. The 
male-female ratio is 7:3. The ratio is close to the CHB patients in Hong Kong (8:2). 
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The main observation period for CHB, CC and DC are 75.4, 66.83 and 63 
months respectively. During different health states, the observation period of each 
patient group is similar. All patients of these three patient groups received a series of 
treatment, including medical consultation, laboratory test, radiology and medication, 
every time they visit Li Ka Shing Specialist Clinic for follow-up. Some patients even 
need to receive liver biopsy, antiviral treatment or even admission to hospitals. One 
can imagine how huge the annual medical burden of the government is to cater for 
these patients' treatments. Results of this study would provide information on how 
HB has a significant impact on overall health care expenditures. 
5.1.4 Calculation method 
First, let's illustrate how the average monthly DMC per patient by the 
government is calculated: 
Example 1: The medical costs of a patient were calculated since he was found to 
have CHB. Totally, he paid 6 outpatient medical visits, laboratory tests, including 8 
ALT, 8 AFP, 6 HB markers and 2 USG, were taken. Nevertheless, he has neither 
received any medication nor stayed in any hospitals. Based on the information, the 
total cost can be calculated as below: 
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Outpatient medical visit : $2,466 
Laboratory test : $3,930 
Radiology : $3,000 
Total : $9,396 
Since the patient was tested positive for carrying CHB until December 2001, 
he did not progress to other health states, so the observation period is 2 years and 8 
months (=32 months). Then we can divide $9,396 by 32 months, getting the result 
$293.63. That means on average, the government spends $293.63 on this patient per 
month. 
Example 2: Another patient was tested positive for carrying CHB on June 
1991. On 23rd April 1993, his health state worsened to CC. Thus, the observation 
period at the health state of CHB is 1 year and 8 months. During this period, he got 
20 medical consultations, laboratory tests, including 19 ALT, 11 AFP, 17 HB markers, 
3 PT/APTT, 7 CBP and 3 USG. For medication, he took Essentiale, Multi-Vitamins, 
Hepatolalk, Panadol, Vitamin K and Erythromycin. He was admitted to hospital for a 
liver biopsy, with a 7-day stay. Besides, he received antiviral treatment for duration 
of 12 weeks. Based on the information, the total cost can be calculated as below: 
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Outpatient medical visit : $8,220 
Laboratory test : $ 10,405 
Radiology : $4,000 
Medications : $617.35 
Liver biopsy : $1,040 
Inpatient care : $2,1434 
Antiviral : $14,867.05 
Total : $60,583.4 
Since the patient stayed in the CHB health state for 1 year and 8 months (=20 
months), we can divide $60,583.4 by 20 months, getting the result $3,029.17. That 
means on average, the government medical burden borne for this patient is $3,029.17 
per month. 
Through the calculation of a patient's DMC per month, then averaging over the 
costs of the patients in the same group, the monthly medical burden of the 
government of these patient groups can be found. 
In order to have a deeper look for the nature of treatment and the associated 
costs of each patient group in this study, Table 4, 4.1-4.7 shows the detailed cost 
breakdown for each cost category and also how difference the cost distribution of 
patients with different length of case histories would be. It should be calculated as 
follows: 
Take the CHB patient group as an example, the time length of each patient's 
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case history is different, so we grouped it into different year bracket starting from 
year 0 to year 16, and each bracket is restricted to one year only. That means if a 
patient whose case history starting from first admission to the December 2001 was 
1 year and 5 months, then he or she will fall into year 1--2 group. After doing this 
categorizing, the annual DMC of each cost category will be calculated in detail. For 
example, there are 18 patients whose case histories were within one year, and each 
patient will receive different investigation and treatment during the diagnosis. We 
record it in detail what treatments each received. Summing up the sub cost item in 
each cost category and then divided the number of patients in each year bracket, 
average over 18 patients in the example. We have a clear picture as to which cost 
items contributed most to the annual DMC. 
5.1.5 Empirical results 
As the latent period of HB is long, when the patients receive medical treatment 
after discovering the disease, the severity of illness varies greatly. Here, the DMC is 
calculated according to patient's profile, not the illness severity of the patient. 
Table (5，5.1) 
Table 5 and 5.1 shows the average monthly DMC of HB-related diseases 
according to their disease status. Table 6 shows the measures of statistical 
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imprecision in the direct cost estimates including the standard deviations, maximum, 
minimum, median and the 9 5 % confidence of the mean estimates. The medical 
expenditures of all items in the patient groups C H B and C C are similar. For all 
patients combined, the cost of medical consultation, laboratory test and radiology 
represented the greatest contribution to the overall D M C , followed by inpatient care, 
liver biopsy and medication. 
Across patient sub-groups, there was a trend towards increased spending on 
inpatient services with disease progression. The more severe the illness is, the higher 
the inpatient cost. The average inpatient cost for C C patients raised 296.67% from 
the average inpatient fee of $52.92 for C H B patients. If the health condition 
deteriorated further to D C , the average inpatient cost increased 315.36% more, 
reaching $871.93. Apart from the inpatient cost, the cost of antiviral treatments 
exhibits similar trend. Following the progression from the less serious C H B to D C , 
on average, the antiviral cost raised 1.36 times per month. In fact, the two findings 
are not difficult to understand. For patients in the stage of C H B , their health states 
are still asymptomatic without obvious symptoms. Few have to receive treatments in 
hospitals, contributing to a smaller proportion of inpatient care cost in the total D M C . 
As the illness progresses, symptoms like jaundice, ascites gradually occur. The 
frequency of hospital stay then increases with disease progression. It is worth noting 
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that the costs multiplied. Indeed, the average annual number of working days lost per 
patient of hospital stays increased with disease progression, ranging from 0.21 days 
for C H B to 3.42 days per year for D C patients. Generally speaking, the investigation 
and treatment received by the patients of C H B and C C are rather simple and 
small-scale. They are medical consultation, liver biopsy to indicate their liver 
function's level of deterioration, observation of changes after receiving antiviral 
treatment and teaching them to perform IV injection themselves. Of course, if the 
patients reach the stage of D C , apart from the previously mentioned treatments, they 
have to receive other treatments like abdomen tapping and blood transfusion. These 
in turn, increase the patients' frequency and duration of hospital stay. Similarly, the 
medical cost of antiviral increases with disease progression with the same reason as 
stated above. 
Figure 3 
In contrast, approximately 80% of costs for patients with C H B were attributable 
to medical consultations, laboratory test and radiology. This shows that investigation 
costs pay a major role in the disease burden for C H B carriers. But as the severity of 
illness increased to become CC, investigation costs fell from the original 80% to 
53.77%. After further deterioration to D C , this part even fell to 31.08%. Other 
treatment costs such as inpatient care and antiviral account for a larger proportion 
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instead of investigation costs. They increased from 18.56% in C H B to 68.97% in D C . 
As noticed from these figures, a trend increases while the other decreases, 
constituting an “X，，sign. Yet, the proportion of medication is very small in all the 
three patient groups, accounting for about 1 % of the total average monthly D M C per 
patient. The reason is that even with the present technology, no complete cure to the 
disease is invented. The only way is to slow down the spread of the disease through 
antiviral treatments. Most medication cannot clean the virus in the patients' liver. 
Therefore, most C H B patients take vitamins like Multi-vitamins, Vitamin B Complex 
Hepatolk and particularly Vitamin K to replenish the loss of nutrients caused by C H B . 
Other common medications include Panadol and antibiotics. 
Figure (4，5) 
D C was the predominant cost driver among HB-related diseases, accounting for 
57.31% of all direct costs. This can be attributed not only to a large number of 
cirrhosis patients in both inpatient care and antiviral categories, but also to the 
intensity of services used by such patients. As for C H B and CC, they both account 
for 22% and 33% of the total D M C . Here, the multiplier effect placed by HB's 
carriers with the progression of disease to the development of complications on Hong 
Kong's medical expenditures. 
Figure 6 
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5.2 Estimation of direct medical cost from the Department of Oncology 
In Hong Kong, H C C is the second most common cause of cancer death. It is the 
second most common cancer in male and the fourth most common cancer in female. 
There is a male predominance with the sex ratio about 3:1 and the age of onset is 
earlier for male. (Public Health Report, 1998) 
5.2.1 Methodology and sample size 
In this part of the study, we adopted a pragmatic approach to calculate the D M C 
of H C C in Hong Kong. The medical history of a sample of H C C patients was 
investigated in this way: From the computer system of the P W H , all patients who 
transferred from the Department of Hepatology to the Department of Oncology 
during 1996 - 2000 were chosen. Patients with H C C caused by C H B became our 
study targets. Eligible subjects include: 1996, n=l; 1997, n=15; 1998, n=18; 1999, 
n=15; 2000, n=10; Total, n=59. For each patient in the sample, the window of 
investigation starts from the first day the patient was diagnosed by the U S G report or 
liver biopsy for having H C C until December 2001, and then within the 
investigation window, the medical history of the patient was studied in details. The 
patients in the study group can be classified into two categories. First, from the first 
investigation day to the end of the study period December 2001), the patient is 
still alive. Second, the patient deceased of H C C before December 2001. So, to 
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calculate the average monthly D M C per patient accurately, two categories (survival 
and deceased) should be calculated separately. In this way, comparison on the burden 
of medical expenditures borne by the government for these two types of patients can 
be made. 
5.2.2 Summary of Costs included in the analysis 
The major cost items to be identified and taken into account are the same as the 
previous group. Besides, as H C C is a very serious disease, apart from general 
treatment costs, other treatment costs including chemotherapy, SIR, operation and 
blood transfusion, have to be considered. The costs of these procedures were 
estimated in accordance with gazetted rate of charges published by the government. 
As for the investigation and treatment costs in this study, the data of 2001 was 
adopted. To avoid extensive adjustments of cost estimates necessitated by the 
government's revision of the rate of charges from time to time, a sample, in which all 
the 59 windows fell within a span of five years, was selected. 
5.2.3Descriptive analysis 
In the target group of study, 59 patients were proven HCC-carriers caused by 
H B . They can be further divided into two sub-groups. One is that the patients are still 
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alive since the first day of window start day to the end of studying period. The other 
is that before the end of studying period, the patients deceased because of liver 
function deterioration. W e found that a total of 45 patients (76.27%) died within the 
observation period; 14 patients (23.73%) survived beyond the observation period. 
The mean time of the survival and deceased group was 31.04 months and 15.92 
months respectively. 
Table 7 
For the subgroup of survival patients, 12 were male and 2 were female, with a 
sex ratio 6:1. Their mean age was 57.86. The mean observation period was 31.04 
months. Given that the duration of observation distribution was skewed to the right, 
the mean was slightly greater than the median — 30.25 months. 
When it comes to the subgroup of deceased patients, their mean age was similar 
to the survival group, with the age 58.84. Yet, the sex ratio is higher than the first one. 
In this group, 35 were male and 10 were female. The sex ratio was 3.5:1. Again, the 
duration of observation distribution was skewed to the right. 
Male is more likely to become HCC-carrier and die of the disease, with an 
earlier onset age than female. The mean onset age of male was 57.2 while that of 
female were 64.6. This shows clearly that H C C has a more serious impact on the 
morbidity and mortality. 
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Apart from medication, the major treatments received by H C C patients include 
chemotherapy, SIR and operation. A m o n g them, nearly 3 9 % of the patients received 
chemotherapy, the most widely adopted treatment. About 17% received other 
treatments to complement chemotherapy in the combination of chemotherapy and 
SIR or chemotherapy and resection at the same time. Since H C C is a very serious 
disease that can bring many complications, leading to different types of treatments 
required by the patients, the duration of hospital stay of H C C patients is very long. 
For the survival group, the average annual number of day of hospital stay per patient 
is 15.23 days. For the deceased group, the average annual number of day of hospital 
stay per patient is 27.87 days. 
5.2.4 Calculation method 
The following examples are illustrated to see how the average monthly D M C 
per patient by the government is calculated: 
Example 1: The medical costs of a patient were calculated since he was found to 
have H C C . Totally, he paid 30 outpatient medical visits, a series of laboratory tests, 
including 23 ALT, 22 AFP, 2 H B markers, 8 PT/APTT, 10 Blood for C B P and 10 
U S G , were taken. In addition, the patient also has been investigated in different 
departments in P W H including Radiology, Diagnostic & Organ Imaging and 
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Radiothereapy. The procedures for H C C investigated are 1 C T Scan and 2 hepatic 
angiogram. He also stayed in the hospital for 28 days; in the mean time, 4 packed 
cells, 5 blood transfusion and 5 platelets were used. There were also medications 
(direct and indirect medications) dispensed and the patient did the resection of the 
tumor during the hospitalization. Based on the information, the total cost can be 
calculated as below: 
Outpatient medical care : $ 12,000 
Laboratory test : $4,620 
Radiology : $14,010 
Inpatient care : $85,736 
Direct medications : $29.2 
Indirect medications : $153.32 
Procedures for HCC^^ : $45,602 
Total : $162,150.52 
Since the patient was tested for carrying H C C from November 1997 until 
December 2001, he survived at December 2001, so the observation period is 4 
years and 1 month (=49 months). W e divide $162,150.52 by 49 months, getting the 
result $3,309.19. That means on average, the government spends $3,309.19 on this 
patient per month. 
Example 2: Another patient was tested for carrying H C C on 29也 September 
14 Including blood transfusion, chemotherapy, liver biopsy, operation, organ imaging, selective 
internal radiation (SIR) and others ^^ 
1997. O n 23rd February 1999, his health state worsened to death. Thus, the 
observation period at the health state of H C C is 1 year and 5 months. During this 
period, he got 33 medical consultations, laboratory tests, including 22 ALT, 27 AFP, 
1 H B markers, 1 Anti-HCV, 7 PT/APTT, 16 CBP, 7 R L F T and 1 Triglycerides and 8 
U S G . Also, there were a lot of procedures for investigation to the patients; there were 
3 C T Scan and 2 hepatic angiogram. He also had medications during this period; 
again, it can be classify as direct and indirect medications as the same as previously 
definition. He was admitted to hospital for 3 liver biopsy, with a 29-day stay. Besides, 
he received chemotherapy for 3 cycles and SIR treatment. Based on the information, 
the total cost can be calculated as below: 
Outpatient medical care : $13,200 
Laboratory test : $6,270 
Radiology ： $18,030 
Inpatient care : $88,798 
Direct medications : $639.60 
Indirect medications : $762.48 
Procedures for H C C : $26916.37 
Total : $154,616.45 
Since the patient stayed in the H C C health state for 1 year and 5 months (=17 
months), we can divide $154,616.45 by 17 months, getting the result $9,095.09. That 
means on average, the government medical burden borne for this patient is $9,095.09 
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per month. 
As for these patients who deteriorated to H C C , it involved substainable medical 
investigation and treatment during the diagnosis; there are a lot of specific items that 
can be calculated in each broad category. In order to have a clearer picture of this, 
patients would fall into different year groups according to their length of their case 
histories. For example, a patient whose case history starting from first admission day 
to the ist December 2001 was 5 months, then he or she would fall into Year 0-1 
group. Then in each year group, each specific cost item under the broad category will 
be taken into calculation. As in the broad category of direct medications, we showed 
previously how we got the average monthly D M C per patient, but we didn't know 
the magnitude of each medication's (e.g. Essentiale, Multi-vitamin, Vitamin B 
Complex...) annual cost in different year groups. Table 8，8.1-8.7 do not only 
provided the detailed cost breakdown for each cost category, but also the cost 
difference among different year groups. So, we get a general picture of how different 
the cost distributions of patients with different length of case histories are. 
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5.2.5 Empirical results 
Table (9，9.1) 
Table 9 and 9.1 shows the D M C of two groups - deceased and survival groups 
of the H C C patients. Table 10 shows the measures of statistical imprecision in the 
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direct cost estimates including the standard deviations, maximum, minimum, median 
and the 9 5 % confidence of the mean estimates. It can be noticed from the table that 
the average monthly D M C per patient for the whole group is affected by three 
components, inpatient care (56.28%), radiology (15.44%) and organ imaging 
(6.22%). Other investigation, consultation and treatment costs only constitute a small 
proportion. For example, outpatient visits only accounts for 5.68%. Laboratory test 
accounts for 5.84%. These two cost items weighted highly in the health state of C H B 
and cirrhosis. But now, the significance is so minor. As for medication, the H C C 
patients' liver function has already severely-deteriorated, many complications such 
as variceal bleeding, hepatic encephalopathy or ascites occurred, leading to an 
increase in the types and dosage of medication received by the patients. So when 
calculating the sole cost for H C C , its share in the D M C is relatively small. This is 
attributable not only to a large number of H C C patients in both inpatient and 
radiology categories, but also to the intensity of services these patients used. 
Some special conditions can be found after careful observation and comparison 
of the medical expenses of various items. For patients in survival group, their 
proportions of operation and SIR in D M C were higher than that in deceased group, 
accounting for 5 % and 1.615% respectively. But for deceased group, the proportion 
was only 4.165% and 0.696%. Yet, for chemotherapy, the opposite occurred. 
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Deceased group had 5.426%, higher than 3.352 of the survival group. The health 
condition of the H C C patients was so severe that even operation and SIR are not 
effective enough to curb the disease. For these patients, doctors usually arrange 3 
treatments, resection, SIR and chemotherapy. If the disease was discovered in an 
early stage, resection and SIR are effective. But reoccurrence cannot be 100% 
guaranteed. If the disease was discovered late, these two treatments are not effective 
anymore. Chemotherapy would then be adopted. There is no fixed treatment duration 
for this type of treatment. It varies greatly with the severity of illness and the 
patient's response. 
Figure 7 
As for medications, it can be classified into two categories: Direct medications 
and indirect medications. Direct medications can bring direct improvement to liver, 
for example, Vitamin K, Essentiate, Hepatolk and Vitamin B Complex. Indirect 
medications cannot improve liver directly. Because H C C patients' liver function has 
deteriorated severely, complications of many kinds ranging from constipation to 
hepatic encephalopthy developed. In short, in absolute amount, the direct medication 
of survival group is higher than deceased group 3 times. In indirect medications, 
however, the deceased group is 5.629 times higher than the survival group. 
Figure 8 
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Deceased group is the predominant cost driver in H C C . Its average monthly 
D M C per patient is 1.48 times higher than that of the other group. In all cost items, 
its medical costs are higher. Particularly indirect medications, chemotherapy and 
inpatient care, its costs are 6.63 times, 4.02 times and 3.27 times higher than that of 
the survival group. The above figures show that the medical expenses do not increase 
in a linear way with the increasing severity of illness. Instead, the increase is in 
several times. 
Figure 9 
To sum up, on the average monthly D M C per patient of HB-related diseases, 
including C H B , CC, D C and H C C , C H B and C C do not place a substantial burden 
on the government's medical expenditures. Nevertheless, as the disease progressed to 
D C , the medical costs doubled. If the disease progressed further to H C C , the increase 
of costs is 8 times, creating serious burden on government's medical expenditures. 
5.3 Kernel estimators 
To get a better understanding of the D M C ' s distribution, computer software 
called XploRe was used to draw the cost distribution of every patient group. In the 
XploRe program, the "gau" in the least cost estimators was selected for drawing. 
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Figure 10-14 shows the cost distribution graphs of every patient group. This software 
was used because the D M C ' s distribution derived from the calculation in this study 
was not a normal distribution. Also, the calculated results were discrete value, 
instead of continuous value. Although histogram can be used to represent the 
information, it is not as clear as Kernel estimators. To clearly represent the cost 
distribution of every patient group, the use of this Kernel estimator is a must. The 
results are as follows: 
Take C H B as an example. 67.2% of the patients' D M C falls within the cost 
range $0-$399. 17.2% falls within $400-$799. As for the rest of the patients, 9.14% 
of the patients with D M C falls within $800-$ 1,199. The D M C of the remaining 6 % 
is between $l,600-$3,599. 
It is noticed from the density function of C C that 77.63% of the patients' D M C 
falls within the cost range $0-$399. About 13.16% falls within $400-$799. The D M C 
of the remaining 9 % is between $800-$6,500. As for D C , the density function is not 
as highly concentrated as that of C H B and CC. 83.33% of the Patients' D M C falls 
within the cost range $0-$ 1,599. The cost variation of this group is not great. 
Compared with the two previously mentioned groups, its distribution is more even. 
In short, from the density function of these three groups, it is not difficult to tell how 
much the government spent for every patient in different health state per month. 
61 
In the patient group of H C C , 14 belong to survival group. 64.29% of the 
patients' D M C falls within the cost range $0-$4,999. About 2 9 % falls within 
$5,000-$9,999. The D M C of the remaining 7.14% is between $10,000-$14,999. One 
can see that the D M C is concentrated in the range $0-$9,999. The variation is small. 
Therefore, the density function of this group looks like an inverted U-shaped. 
As for deceased group, the density function is less concentrated than that of 
survival group. 37.78% of the patients' D M C falls within the cost range $0-$4,999. 
About 33.33% and 8.89% fall within the range $5,000-$9,999 and $10000-$ 14999 
respectively. These three cost groups in fact, account for 80% of the overall D M C . 
From the density function in the figure, it can be noticed clearly that 2 0 % are 
sparsely distributed in the remaining cost range. D M C ' s variation is higher than that 
of survival group, but less concentrated in the three cost range than the survival 
group. 
5.4 Sensitivity to cost variations in medical procedures 
As mentioned in the Empirical Finding's part before, the average monthly D M C 
per patient of different patient groups (CHB, CC, D C and H C C ) is constituted by 
different cost items, some of the items even account for a large percentage in the 
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D M C . A n increase or decrease in the cost of these items can result in significant 
impact on increasing and decreasing the D M C . 
First, let's use C H B as an example. The medical cost of laboratory test accounts 
for 31.65% of the overall D M C . If the cost of the cost item increased by 10%, after 
calculation using the method stated earlier, D M C would increase from the original 
$485.28 to $500.74 at 3.16%. For the patient group C H B , C C and D C , the inpatient 
cost of accounts for the largest percentage of the overall D M C , at 39.81% and 
64.12% respectively. If the cost of the cost item increased by 10%, the D M C of CC's 
group would increase from the original $520.11 to $548.36, an increase of 5.43%. 
And the D M C of D C s group would increase from the original $1,359.8 to $1,446.99， 
an increase of 6.41%. One can expect that in an inflationary economy, the medical 
burden of the government would be a lot heavier. 
As for H C C patients, since they have to receive more intense investigation and 
treatment than the patients of Hepatology, increase in medical costs would add much 
burden to the government. The inpatient cost accounts for a large percentage in the 
overall D M C in these patients, no matter they belong survival or deceased group, at 
43.89% and 57.84% respectively. Similarly, if the cost of the cost item increased by 
10%, after calculation using the method stated earlier, the D M C of survival group 
would increase from the original $4,547.26 to $4,746.84, while that of deceased 
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Chpater 6: Empirical Findings II 
6.1 Estimation of indirect medical costs 
In this study, apart from the calculation of the D M C of all patient groups, the 
calculation of the productivity loss caused by HB-related disease is another objective. 
In this way, a comprehensive insight of CHB's societal impacts and medical 
expenses can be obtained. 
6.1.1 Methodology 
W h e n estimating the patient groups' IMC, focus was placed on the calculation 
of the loss of annual working days per patient ( A W D ) of four patient groups: C H B , 
CC, D C and the survival group of H C C . The study's time frame is the same as that in 
D M C estimation. That means the loss of annual working days of the patients was 
calculated starting from the first day of the patient was tested positive for carrying 
C H B through a period until December 2001. As time pass by, the patient may 
progress from one health state to another. In this case，the patient's medical cost 
calculation in different health states was determined by the liver biopsy or U S G 
report day. After deciding the time frame, the calculation method is as follows: First, 
the number of days for outpatient and inpatient visits is calculated. The causes of the 
loss of working days are threefold: outpatient medical visits, inpatient care visits, and 
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investigation, such as U S G , C T scan and MRI, in the Department of Radiology in the 
hospitals. To calculate A W D , the most direct part is inpatient care part because the 
length of a patient's hospital stays equals to the number of his/ her leave days. So if a 
patient stayed in hospital for 10 days, w e regard him as losing 10 working days. As 
for outpatient visits and treatments in the Department of Radiology, the period since 
the patient arrived at the hospital to his departure, usually half day, was calculated. In 
other words, if a patient paid an outpatient visit to a specialist clinic, or if a patient 
received investigation such as U S G , C T Scan and M R I in a hospital, w e regard him 
as losing half a working day. In this part, such calculation method is used to calculate 
the indirect costs of all four patient groups. 
Assumptions 
The patients are no different from healthy people in terms of working 
competency and daily lives. 
After knowing A W D of every group, let's turn to the calculation of the average 
annual productivity loss per patient (in terms of Hong Kong Dollar) (APL). In this 
part, the economic loss caused by the loss of working day per patient was measured 
based on the G D P per capita per day in 2001 (Hong Kong Monthly Digest of 
Statistics, Jan 2002). Such method was adopted because based on general production 
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function: Y = Af (K, L)，GDP falls with decreasing labor. So the number of working 
days lost is made known, per capita per day can be used to calculate the loss in GDP. 
6.1.2Calculation method 
The following shows some examples of how productivity loss is calculated: 
Example 1: During a patient's health state in C H B , 20 medical consultations and 
7 U S G were received. Nevertheless, there was no inpatient record. His medical 
history lasted for 5 years. Based on the information, his average annual productivity 
loss and the societal loss caused can be calculated as below: 
Number of working days lost: 
Outpatient care visit : (20 x 0.5) days =10 days 
Radiology : (7 x 0.5) days =3.5 days 
Inpatient : (Ox 1) days = 0 days 
Total 13.5 days 
Therefore, the average annual productivity loss is 13.5days/ 5 years = 2.7 days. 
And the loss to society is: 
G D P per capita per day: $131,446/365 = $360.13. 
Average productivity loss per year in terms of H K $ = $360.13 x 2.7days 
=$972.34. 
Example 2: Another patient was diagnosed H C C carrier on August 1996. 
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On 28th M a y 1999, he deceased as his liver function deteriorated. During this period, 
he paid 58 outpatient visits, laboratory tests, including 16 USG and 5 MRI, were 
taken. H e also stayed in the hospital for 105 days. Based on the information, his 
average annual productivity loss and the societal loss caused can be calculated as 
below: 
Number of working days lost: 
Outpatient medical visit : (58 x 0.5) days = 29 days 
Radiology : (21 x 0.5) days = 10.5 days 
Inpatient : (105 x 1) days 二 105 days 
Total 144.5 days 
Therefore, the average annual productivity loss is 144.5days/ 2 years and 9 
months = 52.55 days. And the loss to society is: 
G D P per capita per day: $131,446/ 365 -360.13. 
Average productivity loss per year in terms of H K $ = $360.13 x 52.55days 
-$18,924.83. 
6.1.3 Empirical results 
From the calculation above, the A W D of the four patient groups are 2.5, 2.52, 
5.81 and 10.02 days respectively. Outpatient visits accounts for the largest part in the 
A W D of C H B and C C patients. 73.2% of C H B patients' A W D was caused by visits 
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to specialist clinic for medical consultations with a loss of 1.83 working days. For 
C C patients, outpatient visits accounts for 53.17% in their A W D , with a loss of 1.34 
working days. As for the rest of the patient groups: D C and H C C (survival), inpatient 
care expenses accounts for the largest part in the productivity loss. The A W D of D C 
patients is 5.81 days, in which 3.42 days were hospital stay. The A W D of H C C 
(survival) patients are 15.23 days, in which 7.82 days were hospital stay. The reason 
behind is easy to understand. W h e n the health state of a patient is stable, he or she 
just needs to pay regular outpatient visits to the hospitals. But as his or her health 
state worsens, inpatient treatments are increasingly required. Thus, outpatient visits 
accounts for the largest part in the A W D of C H B and C C patients while inpatient 
care expenses accounts for the largest part in the A W D of D C and H C C (survival). 
After knowing the A W D , the A P L of four patient groups can be obtained, which 
are $901.75, $908.14, $2,092.31 and $5,485.74 respectively. As the health state of 
patients deteriorates, the societal loss multiplies. In Table 11 and 11.1, the statistic 
data of each patient group's A W D and APL, such as standard deviation, maximum, 
minimum and median, were recorded. 
Table (11，11.1) 
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6.2 Estimation of indirect cost (HCC-deceased) 
In the study group, some H C C patients deceased in our study time frame. The 
calculation of the productivity loss caused by this patient group to society is not the 
same as the other groups. In the previously mentioned four groups，the calculation of 
working days loss and the productivity loss were annualized in terms of Hong Kong 
dollar. The calculation for HCC-deceased patients is similar, except that the data was 
not transformed into annual data. 
The average observation period of the patients in this group is 16.18months.It 
means that once the patients were tested HCC-positive until they deceased; the mean 
duration was only 16.18 months. From day of first diagnosis to death, the average 
total number of working days loss is 27.87 days, with inpatient care accounting for 
the largest proportion of the loss at 16.07 days out of 27.87 days. The percentage is 
as high as 57-66%. In terms of Hong Kong dollars, the average total productivity loss 
is $10,035.51 per patient. According to the data provided by the Department of 
Health, 1,200 new cases of H C C patients were found every year due to the progress 
of disease from H B . Thus, one can imagine how great the economic loss per year is. 
Table (12, 12.1) 
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6.3 Premature death 
In calculating the I M C of the patient group H C C (deceased), apart from 
working productivity loss, the premature death H C C caused, which means the period 
of time earlier than natural death, needs to be calculated as well. In the study group, 
male's mean onset age is 57.2, female's is 64.6. The overall mean is 59.711. 
According to the data provided by the Statistical Department, the life expectancy of 
male is 77.2 while that of female are 82.4 (Hong Kong Monthly Digest of Statistics 
Jan 2002). 60 or 65 can be used as retirement age to calculate the economic loss due 
to the premature death caused by H C C . First, subtract the retirement age from the 
patients' onset age. Then multiply the difference by the per capita G D P in 2001. The 
method of calculation is as follows: 
Productivity loss = GDP per capita (2001) x Max [0，retirement age -onset age] 
Table 13 
From Table 13, if the retirement age were 65, the mean productivity loss per 
patient would be $1,039,883,911. But if the retirement age were 60, the mean 
productivity loss would be reduced to $668,914.07 per patient. The economic loss 
would be sizable. 
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6.4Limitation 
Strictly speaking, the calculation of indirect cost stated above is not the best 
method because: 
For one thing, the emphasis of calculating indirect cost should be placed on the 
calculation of individual's welfare loss rather than social cost. If one only focused on 
calculating the working days loss and then the productivity loss of a patient, utility 
loss would be overlooked. To accurately reflect the indirect cost brought by the 
disease, utility loss should be included as well. Let's give an illustration. If a person 
had retired, afterwards he or she was tested positive as a HB-related disease carrier, 
even if his or her outpatient or inpatient care period was long, or premature death 
occurred, there would not be any working days loss, meaning there would not be any 
loss. After retirement, even if the patient were healthy, he or she was no longer a 
member in the workforce. So if the previously mentioned calculation method were 
adopted, the calculated loss caused by his or her disease would be zero. What's more, 
as the disease increased medical expenditure, premature death could have been 
regarded as a relief to society. Therefore, the previously mentioned calculation 
method was not the best one to measure indirect cost. After all, the value of life 
cannot be measured solely by productivity loss. The best way should be the use of 
utility loss to calculate the social welfare loss. 
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In addition, several problems, such as if a patient would be promoted or receive 
higher salary if healthy, if the working ability of a patient were affected after 
suffering from HB-related disease, if the effects would lead to unemployment of the 
patient were ignored.In this sense，it can be said that the calculation method above 
neglected a number of areas. 
Finally, not everything can be calculated easily. For example, would the 
productivity loss of a patient increase with the illness duration? If so, how much 
would the actual loss be? W h o would have a greater productivity loss, a C H B patient 
and an H C G patient? H o w much would their loss differ? What about the time lost to 
work and other activities due to inability to perform activities of daily living while 
sick? What about the time burden on relatives and other unpaid caregivers that have 
to take care of the sick patient at home? All of these additional costs cannot be 
captured within the methodology previously used. Thus, the method, in fact, is not a 
universally accepted method. The only way to do so was conducting the patients 
survey questionnaires. However, this was out of the scope of our study. So within the 
limited information available, it is already the best possible one. The conservative 
figures calculated from this method can be regarded as the minimum acceptable I M C 
because on the one hand, utility loss was not included in the calculation; and on the 
other hand, the loss of promotion opportunity and increase in salary caused by 
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Chapter 7: Conclusion 
This type of study is rather rare in Hong Kong, or even in European and 
American countries. It is hoped that the D M C calculated through this study can more 
or less inspire the academic circle to continue finding a better way of calculating the 
medical cost of other diseases for estimating the social and economic impact of these 
diseases. After knowing the impacts, preventive measures can then be found and put 
into practice. 
Before working on this study, it was preliminary decided to calculate the 
transitional probabilities as C H B progresses to cirrhosis and finally to H C C by using 
Markov chains. In other words, the chances for a C H B patient to progress to the 
health state cirrhosis would be calculated. This study can be more interesting if it can 
compute how much direct medical cost can society save if it can reduce one 
HB-related diseases in the economy. Yet, such calculation is impossible because the 
two prerequisites of Markov chains, that the health condition of every patient must 
be identical in the same health state and that the seriousness of the disease must not 
be affected by the illness duration, cannot be found in reality. Also, their illness 
duration does affect the seriousness of the disease. For example, although cirrhosis 
and H C C are defined as belonging to the same health state, the health condition of a 
patient carrying the disease for one year definitely differs from that of another patient 
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suffering from the disease for ten years. Thus, Markov chains are not applicable.lt 
seems that are could conduct a questionnaire survey so as to get much more 
information about their health states and also their seriousness of the diseases. 
However, this method is beyond the scope of this study as conducting a large sample 
sized survey involves sustainable amount of effort. Even w e could do it, it would not 
be a good way to use a survey's information to do the calculation. It is because the 
existence and type of vaccination received by interviewee would not be accurately 
recalled. The effectiveness of vaccination also varies from person to person. 
As mentioned before, a well-developed computer system for keeping the 
patients' medical case history is still lacking in Hong Kong. Thus, to conduct a more 
comprehensive and large scale research is a tough task. The same problem occurred 
in this study. The effort spent in collection of information, whether manually or not, 
was considerable. In addition, the targets of study were limited. It is hoped that with 
improving record keeping system, future research studies of similar kinds can be 
more accurate and comprehensive. 
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Unit cost of the laboratory tests  
Types Unit Cost Types Unit Cost 
ALT $ 20.00 AFP $ 100.00 
PT/APTT $ 65.00 Blood for CBP $ 45.00 
HBcAg $ 180.00 HBsAg $ 135.00 
HBcAb $ 180.00 Faccal Occult Blood $ 30.00 
AST $ 20.00 LIPID $ 84.()() 
LDH $ 20.00 Ferritin $ 130.()() 
Ascites Fluid $ 65.00 ANA $ 1()0 0() 
RLFT $ 180.00 Haemoglobin Ale $ 3().()() 
Anti-HCV $ 180.00 Scmin Magnesium $ 32.00 
D/C $ 1 ().()() Triglycerides $ 2().()() 
Scmm Tibc $ 100.00 Gamma GT $ 2().0() 
Body Fluid Cc $ 65.00 Blood Gas $ 2().()() 
CPK $ 2().()() CEA $ 14().()() 
TC02 $ 10.00 Scmm Iron $ 1()().()() 
Amylase $ 20.00 IgA-IgA-Igm $ 18().()() 
ASMAM.SM $ 23().()() Anli-HDV $ 18().()() 
HBV-DNA $ 70().()() Anti-HIV $ • . ( ) ( ) 
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Table 2.2 
Unit cost of direct medications  
Type I I Quantity | nit Cost(HK$y 
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Table 2.3 
Unit cost of indirect medications  
Type Quantity nit Cost(HK$) 
Ampicillin 丄 丄 250mg! „.g,l?_12/Ca£_ 
BetnadinrsSution 丄 ; 
CimSidi"ne j i loomgj d.2984/Tab 
品 iii^Jp. 
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Table 3 
Patient Profile (CHB, compensated cirrhosis，decompeansatcd cirrhosis) 
Characteristic Value % of Group 
Number of Patients 194 
Chronic hepatitis B 186 
Compensated cirrhosis 76 
Decompensated cirrhosis 6 
(Number of patients progressed from CHB to Comp.Cirr to Decomp. Cirr) 
Age 
Mean Age 38.4 
Maximum 74 
Minimum 14 
Standard derivation 11.9 
Sex 
Male 135 69.59 
Female 59 31.72 























Compensated Cirrhosis 3 
Decompensated Cirrhosis 2 
Ascites 
CHB 0 
Compensated Cirrhosis () 
Decompensated Cirrhosis 6 
Spider 
CHB 1 
Compensated Cirrhosis 0 
Decompensated Cirrhosis 1 
Variceal Bleeding 
CHB 0 
Compensated Cirrhosis () 
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Patient profile (Hepatocellular carcinoma)  
Characteristic Value % of group 
Number of patients 59.00 
Age ( Whole group) 
Mean 58.61 




Age ( survival group ) 
Mean 57.86 




Age ( deceased ) 
Mean 58.84 
Standard deviation 11.83 
Maximum 80.00 
Minimum 35.00 
Median “ 60.00 
Sex (whole sample ) 
Male 45 76.2712 
Female 12 23.7288 
Sex (survival group) 
Male 12 85.7143 
Female 2 14.2857 
Sex (deceased) 
Male 35 77.7778 





Survival 14 23.7288 
Deceased 45 76.2712 
Complications 
Jaundice 
Survival group 3 




Survival group 3 
Deceased 17 
Spider angiomas 
Survival group 0 
Deceased 1 
Variceal bleeding 
Survival group 0 
Deceased 1 
Hepatic encephalopathy 
Survival group 0 
Deceased 1 
Treatment received 
Chemotherapy 12 38.7100 
SIR 4 12.9000 
Resection 4 12.9000 
Chemotherapy + SIR 5 16.1300 
Chemotherapy + Resection 5 16.1300 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HCC:Ayerage total productivity lost per patient(days)  
Deceased Group 
Outpatient Visits 
Medical Consultation 8.37 
Radiology 3.43 
Inpatient Admissions 16.07 
Hospitalization 
Average total number of working days lost 27.87 





HCC:Productivity lost per patient in terms of HK dolloar  
Deceased Group 
GDP per capita per day(2001) $ 360.13 
Average Total Productivity lost $ 10,035.51 
Standard Deviation 9136.51 
Maximum $ 52,038.21 
Minimum $ 720.25 







































































































































































































































































































































































































































































Age Distribution of patient groups from Department of Hepatology 
Age Distribution(CHB, Compensated & 
35� Decompensated Cirrhosis) 
30 PI 
0 .； 
1 25 - E M a l e .a :: 
^ �� „ B Female g ^ 20 - :::: ::: 
•专 m :: :: 
15 - � n :: o :: :: 
！ 1。 I J 5 ; 目 圓 • 
^ ‘ l l h h k ! n 
Q m rfca \ m IM I：::想 IM M t m _ I源 lA H__^El_i 
12 17 22 27 32 37 42 47 52 57 62 67 72 
Age Group 
Figure 2.1 
Gender Distribution of patient groups from Department of Hepatology 
Gender(HBV) 
I [ 翁 臺 7 0 % 
121 
Figure 3 
Comparsion of inpatient & antiviral's costs 
among different health states 
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Figure 4 
Investigation & treatment Costs 
of 3 health states 細 84 
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122 
Figure 13 
Investigation & treatment Costs among 




_ I 1 1 
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Figure 6 
Comparsion among the average monthly 
direct medical cost of three health states 
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123 
Figure 13 
Comparsion between 3 treatments 
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Comparsion of direct & indirect medications 
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Figure 13 
Average monthly direct medical 
$10,000.00 cost per patient (HCC) 
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Density Function of CHB 
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Figure 11 
Density Function of compensated cirrhosis 
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Figure 12 
Density Function of decompensated cirrhosis 
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Figure 13 
Density Function of HCC(deceased group) 
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Figure 14 
Density Function of HCC(survival group) 
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(Guidelines for recording the direct medical cost in each patient group) 
Chronic Hepatitis B 
Patients with chronic Hepatitis B confirmed with laboratory testing, without cirrhosis. 
Outpatient visits for Chronic H B V 
Frequency and cost of outpatient medical care visits for patients with chronic Hepatitis B 
without cirrhosis. 
L盛Q!啦幽--fcL-Q廻ik:匪Y-— 
Frequency and cost of laboratory tests. For example, tests used to monitor liver function such 
as ALT/AST. 
Antivirals 
Antiviral agents used to treat hepatitis B, e.g., interferon and lamivudine. 
Inclusions 
Any antiviral agent used in common practice, e.g., thymosin-alpha and/or herbal medications 
in addition to standard antivirals such as interferon and lamivudine. 
Co]JejCtLon.Protgcgl 
Include in "notes" section treatment regimen used to calculate cost, i.e.. Drug, Dose, Duration 
for each medication. 
Compensated Cirrhosis 
Full Definition 
Patients with Hepatitis B and compensated cirrhosis (but no complications such as variceal 
bleeds, ascites, or hepatic encephalopathy). These patients could be identified through clinical 
signs such as jaundice, spider angiomas, or gynecomastia. Their medical resource utilization 
and costs may be very similar to patients in the Chronic Hepatitis B category. 
Outpatient visits for Compensated Cirrhosis. 
Frequency and cost of outpatient medical care visits for patients with Hepatitis B and 
compensated cirrhosis. 
Laboratory tests for Compensated Cirrhosis. 
Frequency and cost of laboratory tests. For example, tests used to monitor liver function such 
as ALT/AST. 
locjusioiis 
Include tests for monitoring patients with hepatitis B (and compensated cirrhosis), and tests 
for monitoring treatments. 
128 
Medications for Compensated Cirrhosis 
Cost of any medications used to treat complications in compensated cirrhosis (spider 
angiomas, gynecomastia, and jaundice) in patients with Hepatitis B and compensated 
cirrhosis. 
Exclusions 
Do not include antivirals in this item. Please use the specific data item provided for antivirals. 
Antivirals.... 
Antiviral agents used to treat hepatitis B, e.g., interferon and lamivudine. 
Inclusions 
Any antiviral agent used in common practice, e.g., thymosin-alpha and/or herbal medications 
in addition to standard antivirals such as interferon and lamivudine. 
Decompensated Cirrhosis 
Full Definition 
Patients with Hepatitis B with decompensated cirrhosis. Decompensated cirrhosis is defined 
as a patient with one or more of the following complications: variceal bleeding, hepatic 
encephalopathy, or ascites. Patients with Hepatitis B and one of the above complications 
should be identified. Data could then be collected for a) 1 year following the occurence of the 
defining event; or，preferably b) 1 year before death. 
Outpatient visits for Decompensated Cirrhosis. 
Frequency and cost of outpatient medical care visits for patients with Hepatitis B and 
decompensated cirrhosis. 
Laboratory tests for Decompensated Cirrhosis. 
Frequency and cost of laboratory tests. For example, tests used to monitor liver function such 
as ALT/AST. 
Medications for Decompensated Cirrhosis. 
Cost of medications used to treat patients with Hepatitis B and decompensated cirrhosis 
Medications used to treat specific complications; e.g., variceal bleeding, ascites. 
Antivirals 
Antiviral agents used to treat hepatitis B, e.g., interferon and lamivudine 
Any antiviral agent used in common practice, e.g., thymosin-alpha and/or herbal medications 
in addition to standard antivirals such as interferon and lamivudine. 
Inpatient admissions for Decompensated Cirrhosis. 
Frequency and cost of inpatient admissions (hospitalization) for patients with Hepatitis B and 
decompensated cirrhosis. 
Admissions related to the management of decompensated cirrhosis 
Procedures for Decompensated Cirrhosis. 





Outpatient visits for hepatocellular carcinoma 
Frequency and cost of outpatient medical care visits for patients with Hepatitis B and 
hepatocellular carcinoma. 
Labs for Hepatocellular Carcinoma. 
Frequency and cost of laboratory tests. For example, tests used to monitor liver function such 
as ALT/AST. 
Medications for Hepatocellular Carcinoma 
Cost of medications used to treat patients with Hepatitis B and hepatocellular carcinoma. 
Includes chemotherapy 
Antivirals 
Antiviral agents used to treat hepatitis B, e.g., interferon and lamivudine. 
Ally antiviral agent used in common practice, e.g., thymosin-alpha and/or herbal medications 
in addition to standard antivirals such as interferon and lamivudine. 
Inpatient admission for hepatocellular carcinoma 
Frequency and cost of inpatient admission (hospitalization) for patients with Hepatitis B and 
hepatocellular carcinoma. 
Procedures for Hepatocellular Carcinoma 
Including, but not limited to radation therapy, surgical procedures (e.g., resection) 
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Appendix 2 
Screening criteria proposed by Wilson and Jungner (1968) 
• The condition sought should be an important health problem. 
• There should be an accepted treatment for patients with recognized disease. 
Facilities for diagnosis and treatment should be available. 
• There should be a recognizable latent or early symptomatic stage. 
• There should be a suitable test or examination. 
• The test should be acceptable to the population. 
• The natural history of the condition, including development from latent to 
declared disease, should be adequately understood. 
參 There should be an agreed policy on w h o m to treat as patients. 
• The cost of case finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical 
care as a whole. 
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Estimated HBV carriage rate by age group in Hong Kong  
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